에 대한 최신 뉴스 Prestige Consumer (NYSE:PBH) 주식

PRESTIGE CONSUMER HEALTHCARE

Prestige Consumer

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer Healthcare Inc

Pathfinder Bancorp Inc

PARAMOUNT BED CO ORD by Paramount Bed Co., Ltd.

Paramount Bed Holdings Co Ltd

PBS Holding Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) has outperformed the market over the past 15 years by 5.71% on an annualized basis producing an average annual return of 17.56%. Currently, Prestige Consumer has a market capitalization of $4.23 billion. 
Buying $100 In PBH: If an investor had bought $100 of PBH stock 15 years ago, it would be worth $1,115.32 today based on a price of $85.68 for PBH at the time of writing.
<h3>Prestige Consumer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749570312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Prestige Consumer Stock In The Last 15 Years

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) has outperformed the market over the past 15 years by 5.46% on an annualized basis producing an average annual return of 17.46%. Currently, Prestige Consumer has a market capitalization of $4.20 billion. 
Buying $1000 In PBH: If an investor had bought $1000 of PBH stock 15 years ago, it would be worth $11,018.13 today based on a price of $85.06 for PBH at the time of writing.
<h3>Prestige Consumer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749243626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Prestige Consumer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) short percent of float has risen 8.64% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 5.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Prestige Consumer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748955632_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Prestige Consumer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Prestige Consumer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Prestige Consumer's peer group average for short interest as a percentage of float is 3.84%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Prestige Consumer?

WIIM

Prestige Consumer Healthcare shares are trading higher after the company reported a Q4 adjusted EPS beat.

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) is looking for FY2026 GAAP EPS of $4.70-$4.82 vs $4.81 analyst estimate. sees sales of $1.140 billion-$1.155 billion vs $1.16 billion analyst estimate.

Guidance

Prestige Consumer Sees FY2026 GAAP EPS $4.70-$4.82 vs $4.81 Est; Sees Sales $1.140B-$1.155B vs $1.16B Est

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.30 by 1.54 percent. This is a 29.41 percent increase over earnings of $1.02 per share from the same period last year. The company reported quarterly sales of $276.99 million which missed the analyst consensus estimate of $289.35 million by 4.27 percent. This is the same as the same period last year.

Earnings

Earnings Beats

Earnings Misses

Prestige Consumer Q4 Adj. EPS $1.32 Beats $1.30 Estimate, Sales $276.99M Miss $289.35M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

In the last three months, 4 analysts have published ratings on Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $98.5, along with a high estimate of $104.00 and a low estimate of $93.00. Marking an increase of 6.2%, the current average surpasses the previous average price target of $92.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1742590848_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Prestige Consumer among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryland Conrad</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Prestige Consumer. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prestige Consumer compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Prestige Consumer's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Prestige Consumer's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prestige Consumer analyst ratings.</a>
<h2>All You Need to Know About Prestige Consumer</h2>
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
<h3>Understanding the Numbers: Prestige Consumer's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Prestige Consumer displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.68%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prestige Consumer's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.47%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Prestige Consumer's ROA stands out, surpassing industry averages. With an impressive ROA of 1.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Prestige Consumer's debt-to-equity ratio is below the industry average at 0.57, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 4 Analysts Discuss Prestige Consumer Stock

CORRECTION: RBC Capital analyst Ryland Conrad maintains Premium Brands Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBH#TSX">PBH</a>) with a Sector Perform and raises the price target from C$96 to C$97. (Stock Name Change From Prestige Consumer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbh#NYSE">PBH</a>) To (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBH#TSX">PBH</a>) Premium Brands Holdings.

Price Target

TSX:PBH

CORRECTION: RBC Capital Maintains Sector Perform on Premium Brands Hldgs, Raises Price Target to C$97 (Stock Name Change From Prestige Consumer (NYSE:PBH) To (TSX: PBH) Premium Brands Holdings.

RBC Capital analyst Ryland Conrad maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Sector Perform and raises the price target from $96 to $97.

RBC Capital Maintains Sector Perform on Prestige Consumer, Raises Price Target to $97

<h3>Companies Reporting Before The Bell</h3>
• Sunlands Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) is likely to report earnings for its fourth quarter. 
• Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) is likely to report earnings for its fourth quarter. 
• Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $5.37 million. 
• Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $1.60 billion. 
• MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is expected to report earnings for its second quarter. 
• NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.42 per share on revenue of $2.85 billion. 
• 51 Talk Online Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COE#AMEX">COE</a>) is expected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is projected to report earnings for its fourth quarter. 
• Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) is projected to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRI

MBRX

MNSO

SOWG

TIVC

Earnings Scheduled For March 21, 2025

Oppenheimer analyst Rupesh Parikh maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Outperform and raises the price target from $87 to $93.

Oppenheimer Maintains Outperform on Prestige Consumer, Raises Price Target to $93

Canaccord Genuity analyst Susan Anderson maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $93 to $100.

Canaccord Genuity Maintains Buy on Prestige Consumer, Raises Price Target to $100

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $95 to $104.

DA Davidson Maintains Buy on Prestige Consumer, Raises Price Target to $104

Prestige Consumer Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 adjusted EPS guidance above estimates.

Prestige Consumer Healthcare Raises FY25 Adj EPS Outlook From $4.40 - $4.46 To $4.50 Vs. $4.44 Est.

Prestige Consumer Healthcare Trims FY25 Revenue outlook From $11.25B - $11.40B To $11.28B - $11.32B Vs. $12.21B Est.

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly adjusted earnings of $1.22 per share which beat the analyst consensus estimate of $1.16 by 5.17 percent. This is a 15.09 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $290.32 million which beat the analyst consensus estimate of $286.48 million by 1.34 percent. This is a 2.68 percent increase over sales of $282.74 million the same period last year.

Prestige Consumer Q3 Adj $1.22 Beats $1.16 Estimate, Sales $290.32M Beat $286.48M Estimate

AAMI

AGCO

AMRK

AMZN

APTV

CIGI

CRNC

DOCS

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

ILMN

INTR

KVUE

LADR

LESL

Laboratory Corporation Of America Holdings

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Management

Prestige Consumer Healthcare CFO Expands Role To Include Chief Operating Officer Responsibilities

Press Releases

Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Earnings Results

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results

Prestige Consumer Healthcare Inc. Expands CFO Christine Sacco's Role to Include Chief Operating Officer Responsibilities

Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earnings Results Date and ICR Conference Presentation

Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook

Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

Health Care

General

Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Comments

Prestige Consumer

뉴스

에 대한 최신 뉴스 Prestige Consumer (NYSE:PBH) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌